BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1726958)

  • 1. [Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
    Gutiérrez J; Osorio G; García H; Vacarezza R; Cao C
    Rev Med Chil; 1991 Sep; 119(9):990-1000. PubMed ID: 1726958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].
    Pittrová H; Koza V; Vozobulová V; Cetkovský P; Skopek P; Jungerová J; Cepelák V
    Vnitr Lek; 1989 Dec; 35(12):1177-82. PubMed ID: 2483776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of three polychemotherapy programs in non-Hodgkin's lymphomas.
    Konopka L; Pawelski S
    J Chemother; 1989 Jul; 1(4 Suppl):1259-62. PubMed ID: 16312857
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination chemotherapy for advanced diffuse large cell lymphoma. The adverse effects of bone marrow invasion, gastrointestinal tract involvement or high bulk disease.
    Jacobs P; King HS; Dent DM
    Haematologia (Budap); 1990; 23(1):41-7. PubMed ID: 1697822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-hodgkins lymphoma.
    Mead G; Woodcock J; Young C
    Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
    [No Abstract]   [Full Text] [Related]  

  • 14. [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
    Wang A; Luo Y; Wang Z
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):215-7. PubMed ID: 10920901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA) in intermediate- and high-grade lymphoma: an effective short-course regimen.
    Baer MR; Stein RS; Greer JP; Wolff SN; Hainsworth JD; Flexner JM
    Cancer Treat Rep; 1986 Jun; 70(6):785-7. PubMed ID: 3488125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
    Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
    Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment by the CHOP protocol in malignant non-Hodgkin lymphomas with high malignancy].
    Gociu M; Leahu S; Stoica I; Iofciulescu A; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(1):47-51. PubMed ID: 2899347
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy for non-Hodgkin's lymphoma].
    Kuraishi Y; Usui N; Dobashi N
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2210-6. PubMed ID: 9881077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study of 1st generation versus 2d generation (CAVPE) combinations in intermediate and high-grade lymphomas].
    Pavlovsky S; Milone G; Somoza N; Corrado C; Magnasco H; Cerutti I; Saslavsky J; Fernández I; Bruno S
    Sangre (Barc); 1993 Feb; 38(1):17-23. PubMed ID: 8470032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.